Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an interme… Read more
Market Cap & Net Worth: Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)
Starlake Bioscience Co Inc Zhaoqing Guangdong (SHG:600866) has a market capitalization of $1.82 Billion (CN¥13.37 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #7365 globally and #1243 in its home market, demonstrating a 6.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Starlake Bioscience Co Inc Zhaoqing Guangdong's stock price CN¥8.05 by its total outstanding shares 1661472616 (1.66 Billion).
Starlake Bioscience Co Inc Zhaoqing Guangdong Market Cap History: 2015 to 2026
Starlake Bioscience Co Inc Zhaoqing Guangdong's market capitalization history from 2015 to 2026. Data shows growth from $1.86 Billion to $1.82 Billion (0.58% CAGR).
Starlake Bioscience Co Inc Zhaoqing Guangdong Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Starlake Bioscience Co Inc Zhaoqing Guangdong's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap is 0.08 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.55x
Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap is 1.55 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.86 Billion | $729.76 Million | -$422.35 Million | 2.55x | N/A |
| 2016 | $1.60 Billion | $679.85 Million | $24.31 Million | 2.36x | 65.96x |
| 2017 | $1.04 Billion | $686.97 Million | -$158.27 Million | 1.52x | N/A |
| 2018 | $711.03 Million | $859.11 Million | $42.28 Million | 0.83x | 16.82x |
| 2019 | $1.01 Billion | $1.05 Billion | $149.55 Million | 0.96x | 6.72x |
| 2020 | $1.13 Billion | $1.12 Billion | $148.71 Million | 1.01x | 7.60x |
| 2021 | $1.41 Billion | $4.07 Billion | $152.14 Million | 0.35x | 9.29x |
| 2022 | $1.34 Billion | $17.49 Billion | $608.33 Million | 0.08x | 2.21x |
| 2023 | $1.06 Billion | $17.37 Billion | $677.95 Million | 0.06x | 1.56x |
| 2024 | $1.47 Billion | $17.33 Billion | $943.15 Million | 0.08x | 1.55x |
Competitor Companies of 600866 by Market Capitalization
Companies near Starlake Bioscience Co Inc Zhaoqing Guangdong in the global market cap rankings as of March 18, 2026.
Key companies related to Starlake Bioscience Co Inc Zhaoqing Guangdong by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Starlake Bioscience Co Inc Zhaoqing Guangdong Historical Marketcap From 2015 to 2026
Between 2015 and today, Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap moved from $1.86 Billion to $ 1.82 Billion, with a yearly change of 0.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.82 Billion | +15.83% |
| 2025 | CN¥1.57 Billion | +7.42% |
| 2024 | CN¥1.47 Billion | +38.84% |
| 2023 | CN¥1.06 Billion | -21.42% |
| 2022 | CN¥1.34 Billion | -4.97% |
| 2021 | CN¥1.41 Billion | +25.05% |
| 2020 | CN¥1.13 Billion | +12.39% |
| 2019 | CN¥1.01 Billion | +41.40% |
| 2018 | CN¥711.03 Million | -31.74% |
| 2017 | CN¥1.04 Billion | -35.03% |
| 2016 | CN¥1.60 Billion | -13.97% |
| 2015 | CN¥1.86 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Starlake Bioscience Co Inc Zhaoqing Guangdong was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.82 Billion USD |
| MoneyControl | $1.82 Billion USD |
| MarketWatch | $1.82 Billion USD |
| marketcap.company | $1.82 Billion USD |
| Reuters | $1.82 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.